#5 - AbbVie (NYSE:ABBV)
AbbVie (NYSE:ABBV) - Abbvie is a good example of a stock that may face some challenges as a pure growth play, but remains an exceptional dividend stock. Investors can virtually bank on their 4.6% dividend yield as the company has a 45-year streak of increasing their dividend. The present and future direction of Abbvie’s stock centers around their popular, and best-selling, drug Humira. The drug, which is proven to treat symptoms of Crohn’s disease and rheumatoid arthritis (among other conditions), saw its EU patent expire in 2018 and the U.S. patent for Humira will expire in 2023. However, while the company is noticing a drop-off in international sales, AbbVie has negotiated licensing agreements with competitors who will be introducing biosimilar drugs. But Humira is not expected to give much ground to its competitors. The market research company EvaluatePharma speculates that Humira still has a long run – with projected sales of over $15 billion in 2024. The company is also projecting $35 billion in annual risk-adjusted sales from drugs other than Humira by 2025. That amounts to more than what the company made last year from Humira.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $169.43
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $178.21 (5.2% Upside)
